🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥hot out now: GALA-RIF trial🔥 👥136 ArLD liver fibrosis 💊Rifaximin vs placebo 💉biopsy controlled 🗓️18 mo treatment RCT results: 👉No diff. in fibrosis regression 👉Rifax Tx halted fibrosis progression The Lancet Gastroenterology & Hepatology GALAXY Mads Israelsen doi.org/10.1016/S2468-…

Join our NORDIC NASH symposium for free🤩 April 20th💪 World leading experts with short, sharp and exiting presentations on the newest updates in NASH research! Check out the full program: linkedin.com/feed/update/ur… See you in Odense or online🤩 We can’t wait👏

👉What does the future hold for NASH patients? Don’t miss out on this great opportunity, April 20th F2F in Odense or online. 👉🌟🌟🌟 FACULTY

Fatty liver disease ↗️   👉 Late diagnosis 👉 Healthcare pathways in #NAFLD? 👉Today Sunday we tried something different ➡️ Drop-in Fibroscan in T2D / BMI>30 👉Announced on FB and local media ➡️102 scanned 📣14% TE>9Kpa 😳 Most had never had a liver check  #Livertwitter

#NordicNASHOdense2023 in 3 days- April 20th   Join 200 colleagues F2F/online in Odense Free: Still online availabilities   👉When to refer and how to follow-up? 👉What interventions can we offer? 👉Current best practice rsd.plan2learn.dk/Classes.aspx?i…

How to screen for liver fibrosis? Our paper is out in Journal of Hepatology! 🇩🇰ELF, FIB4, NFS in 3,378 people 🔊Biopsy if LSM≥8 kPa TE≥8: 3.4% general pop, 12% at-risk ALD, 14% at-risk NAFLD Optimal screening: FIB4➡️ELF if indeterminate➡️  confirm w. TE 🔗doi.org/10.1016/j.jhep…

Casefinding is difficult in the population, but we’re getting better! ❌Poor correlation btw TE & ELF ❎Pathway detected 1/3 of those w TE≥8kPa ✳️...and 2/3 of those w TE≥12 kPa ✅Two-tiered referral reduced false positives from 35% to 7.8% vs FIB-4 ✅costs 123💶 per person

27% of screening positives had biopsy-verified advanced fibrosis AUCs, from best to worst: TE ➡️ ELF ➡️ FIB4 ➡️ NFS 🙏Thanks to LiverScreen H2020 Novo Nordisk Foundation #Horizon2020 FLASH - Liver Research

PhD defence by Charlotte Wernberg Why NAFLD? ‼️Steatosis in 1/3 of all adults 🆙Prevalence 🤷‍♀️Lack of NILTs for NASH Tissue plasticity? ATLAS Publication 1: doi.org/10.1002/hep.32… #TREM2 Supervisors Aleksander Krag MetteMunkLauridsen Opponents Maru Rinella MD Filip K. Knop

Festival of Research 2023 at @SUND_SDU > 200 citizens vistited our FLASH - Liver Research LIVER booth 💪🙏   👉Awareness of liver health in our community⬆️ 👉Impact of #alcohol #obesity #NASH Inspired by EASLnews outreach Love your liver✅ Hepatology is hot ✅ easl.eu/impact-project…

Our partners LiverScreen H2020 are hosting a networking session at #EASLCongress! 🗣The faculty are looking forward to meet and discuss with you their work in liver fibrosis screening. Join us! 📅 Friday 23 June, 10:00 - 10:30 📌General Hepatology Track Hub All information on

This large study confirms that the use of FIB-4 for fibrosis screening leads to a high number of FALSE POSITIVE cases and unnecessary referrals. Sequential use with other biomarkers (ie. ELF) minimizes this limitation. shorturl.at/dhkN8 #livertwitter #medtwitter

Detecting silent liver fibrosis is like playing hide and seek. You must know you're in the game & who you're looking for. Randomly seeking behind broken glasses for someone not doing the "peek-a-boo" leads to failure. What are our possibilities? thieme-connect.com/products/ejour…

Maja Thiele shows the flowchart of the largest trial researchers and industries will perform in the field of liver diseases LiverAim KOM #changingtheparadigm Aleksander Krag Salvatore Piano Jeffrey V. Lazarus Jörn Schattenberg @miquelsb2 Innovative Health Initiative EASL Education EASLnews

Intense preparations for FLASH - Liver Research presentations at #EASLcongress 1️⃣secretary general Aleksander Krag 2️⃣🌟top posters Katrine Tholstrup Bech @NikolajTorp_ 3️⃣oral pres Mads Israelsen Helle Lindholm Schnefeld Johanne Kragh Hansen, MD, PhD 4️⃣invited pres 🗣️🎤 🥳….lots of fun

For those missing out on today’s #EASLstudio at #EASLcongress I highly recommend watching it on demand if wanting to learn more about bridging the gap between MASLD and ALD. Thank you for a nice session Maja Thiele Mads Israelsen ELISA POSE Alexandre Louvet and Christophe Moreno

🎉Time to celebrate! 3⃣0⃣,0⃣0⃣0⃣ individuals from across different European countries have been included in the @LiverScreen project. A HUGE thank you goes to all participating subjects, study physicians and nurses, coordinators and administrators from the Consortium.

Coming soon: major results from LiverScreen H2020 #Horizon2020 🗣️🎤Liver stiffness follow up 2-4 years after screening presented by Katrine Tholstrup Bech 🧍n=3,373 🇪🇸🇳🇱🇩🇰 🤏1.3% progressed from <8 kPa to >10 kPa 👉8.8% progressed >20% from >8 kPa

I am so proud of our nurse researcher Helle Lindholm Schnefeld Now: on the big stage presenting data on socioeconomic disparities across MASLD↔️MetALD ↔️ALD Next: phd project submission - we will investigate stigma and health disparities, and how these affects consequences of screening

Big day today: my first international conference oral presentation! I’ll be talking about PEth vs self-reported alcohol use in individuals at risk of steatotic liver disease. Catch me in de Groote Room, Alcohol Session, at 17:00 (OS-030-YI). Excited and ready! #EASLCongress